# Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels

> **NCT05458102** · PHASE1 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 18 (actual)

## Conditions studied

- Human Immunodeficiency Virus Type 1 (HIV-1) Infection

## Interventions

- **DRUG:** Vesatolimod
- **DRUG:** Cobicistat
- **DRUG:** Voriconazole
- **DRUG:** Rifabutin

## Key facts

- **NCT ID:** NCT05458102
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-08-19
- **Primary completion:** 2023-05-01
- **Final completion:** 2023-05-01
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Sponsor's decision to change the clinical development plan of this molecule. This decision is not based on efficacy or safety concerns.
- **Last updated:** 2024-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05458102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05458102, "Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05458102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*